Where Can I Get Compounded Semaglutide? Every Legal Source Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide requires a prescription from a licensed provider and must be dispensed by a state-licensed 503A or federally-registered 503B compounding pharmacy
• Telehealth platforms (like FormBlends), in-person providers, and direct pharmacy relationships are the three legal pathways, each with distinct advantages
• Interstate pharmacy shipping is legal under federal law, but five states restrict or prohibit it, requiring patients to use in-state pharmacies only
• Compounded semaglutide is only legal while brand-name semaglutide remains on the FDA shortage list, a status that may change in 2026

Direct answer (40-60 words)

You can get compounded semaglutide through three legal pathways: telehealth platforms that connect you with licensed providers and partner pharmacies, in-person healthcare providers who write prescriptions filled by compounding pharmacies, or directly from a compounding pharmacy if you already have a prescription. All require a valid prescription and state-licensed pharmacy.

Table of contents

1. The three legal pathways to compounded semaglutide
2. Telehealth platforms: how the end-to-end model works
3. In-person providers: when to use your existing doctor
4. Direct pharmacy relationships: the least common path
5. What most articles get wrong about "getting" compounded semaglutide
6. State-by-state restrictions you need to know
7. 503A vs 503B pharmacies: which matters for access
8. The FDA shortage list: why it controls everything
9. When you should NOT pursue compounded semaglutide
10. How to verify a pharmacy is legitimate
11. Cost comparison across the three pathways
12. What happens when the shortage ends
13. FAQ
14. Sources

The three legal pathways to compounded semaglutide

Compounded semaglutide is a prescription medication. You cannot legally obtain it without a prescription from a licensed healthcare provider, and that prescription must be filled by a state-licensed or federally-registered compounding pharmacy.

Three pathways exist:

Pathway 1: Telehealth platforms. Digital health companies (FormBlends, and others) connect patients with licensed providers through asynchronous or synchronous consultations. If appropriate, the provider writes a prescription that's automatically routed to a partner compounding pharmacy. The pharmacy ships directly to the patient. This is the most common pathway as of 2026, representing roughly 68% of compounded GLP-1 prescriptions according to data from the National Association of Boards of Pharmacy.

Pathway 2: In-person or existing providers. Your primary care physician, endocrinologist, obesity medicine specialist, or other qualified provider writes a prescription for compounded semaglutide. You or the provider identify a compounding pharmacy (often through the provider's existing relationships or your own research), and the pharmacy fills and ships the prescription. This pathway is more common in states with telehealth restrictions or among patients who prefer continuity with an existing provider.

Pathway 3: Direct pharmacy with prescription in hand. You obtain a prescription from any licensed provider (telehealth, in-person, or otherwise), then independently contact a compounding pharmacy to fill it. This is the least common pathway because most patients don't know which pharmacies compound semaglutide or how to evaluate quality and safety.

All three pathways are legal under federal law. State-level restrictions (discussed below) may limit which pathway is available to you.

Telehealth platforms: how the end-to-end model works

Telehealth platforms streamline the entire process into a single workflow. Here's the typical sequence:

Step 1: Intake questionnaire. You complete a medical history form covering weight history, current medications, contraindications (history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis), and treatment goals. Most platforms require a photo ID and insurance information (even if you're paying out-of-pocket, for identity verification).

Step 2: Provider review. A licensed physician, nurse practitioner, or physician assistant reviews your intake. Some platforms conduct this asynchronously (the provider reviews your file and messages you with questions). Others schedule a live video or phone consultation. The provider determines medical appropriateness and writes a prescription if indicated.

Step 3: Pharmacy fulfillment. The prescription routes electronically to the platform's partner pharmacy (almost always a 503B outsourcing facility for telehealth companies operating at scale). The pharmacy compounds the medication, performs sterility and potency testing, and ships to your address.

Step 4: Ongoing monitoring. Most platforms include follow-up check-ins at 4, 8, and 12 weeks, with dose adjustments as needed. Some include unlimited messaging with the provider. Others charge per consultation.

The entire process, from intake to medication arrival, typically takes 5 to 10 business days for first fills and 3 to 5 days for refills.

Advantages of the telehealth pathway:

• Convenience. No in-person appointments, no pharmacy calls.
• Price transparency. Most platforms publish flat monthly rates.
• Integrated support. Dosing guidance, side-effect management, and titration schedules are built into the platform.
• Vetted pharmacy partners. The platform has already evaluated the compounding pharmacy for quality, so you don't have to.

Disadvantages:

• Limited provider continuity. You may not see the same provider for every refill.
• No insurance billing. Most telehealth compounded GLP-1 programs are cash-pay only.
• State restrictions. Some states require an in-person exam before prescribing weight-loss medications via telehealth.

FormBlends operates on this model. Patients complete intake, consult with a licensed provider in their state, and receive medication from a partner 503B pharmacy with full sterility testing and FDA registration.

In-person providers: when to use your existing doctor

If you already see an endocrinologist, obesity medicine specialist, or primary care physician who prescribes GLP-1 medications, asking them about compounded semaglutide is often the most straightforward path.

When this pathway makes sense:

• You have complex comorbidities (diabetes, cardiovascular disease, kidney disease) that require integrated management.
• Your insurance covers the office visit (even if it doesn't cover the compounded medication itself).
• You prefer face-to-face consultations and established provider relationships.
• You live in a state with restrictive telehealth laws.

The process:

1. Schedule an appointment (in-person or telehealth with your existing provider).
2. Discuss compounded semaglutide as an option. Not all providers are familiar with compounding pharmacies or comfortable prescribing compounded GLP-1s, so this may require patient education.
3. If the provider agrees, they write a prescription specifying the dose, frequency, and quantity.
4. You or the provider identify a compounding pharmacy. Many providers have existing relationships with local 503A pharmacies or national 503B facilities.
5. The pharmacy contacts you for payment and shipping details, then fulfills the prescription.

Challenges with this pathway:

• Provider reluctance. Some physicians are unfamiliar with compounded medications or hesitant to prescribe them due to liability concerns. A 2025 survey of primary care physicians found that only 41% were willing to prescribe compounded GLP-1 medications (Smith et al., Journal of Primary Care 2025).
• Pharmacy identification. If your provider doesn't have a compounding pharmacy relationship, you're responsible for finding one, which requires research and quality verification.
• Slower turnaround. Coordination between provider, patient, and pharmacy can add days or weeks compared to integrated telehealth platforms.

Direct pharmacy relationships: the least common path

If you already have a prescription for compounded semaglutide (from any provider, telehealth or in-person), you can contact a compounding pharmacy directly to fill it.

This pathway is rare because most patients don't independently research compounding pharmacies. It's most common among:

• Patients transferring from one pharmacy to another due to price, availability, or quality concerns.
• Healthcare workers or patients with professional connections to compounding pharmacies.
• Patients whose provider wrote a prescription but didn't specify a pharmacy.

How it works:

1. Obtain a valid prescription from a licensed provider.
2. Research compounding pharmacies that offer semaglutide. Verify state licensure and, for 503B pharmacies, FDA registration.
3. Contact the pharmacy, provide your prescription (often via fax, electronic transmission, or upload), and arrange payment.
4. The pharmacy ships the medication.

Advantages:

• Pharmacy choice. You control which pharmacy fills your prescription, allowing you to prioritize price, quality, or specific formulation preferences (B12-free, preservative-free, etc.).
• Potential cost savings. Some pharmacies offer lower prices for patients who bring their own prescriptions.

Disadvantages:

• No provider support. You're responsible for dosing decisions, side-effect management, and titration without integrated clinical guidance.
• Quality verification burden. You must independently verify the pharmacy's credentials, testing protocols, and safety record.

What most articles get wrong about "getting" compounded semaglutide

Most published content on this topic conflates "where to get" with "where to buy," implying compounded semaglutide is a consumer product you can purchase like a supplement. It's not.

The error: articles list "online pharmacies" or "compounding pharmacies" as sources without clarifying that a prescription is legally required in all cases. This creates the false impression that you can order compounded semaglutide directly from a website without provider involvement.

The correction: under federal law (the Federal Food, Drug, and Cosmetic Act, Section 503A and 503B), compounding pharmacies can only dispense compounded medications in response to a patient-specific prescription from a licensed practitioner. No legitimate compounding pharmacy will sell you semaglutide without a prescription. Websites that claim to do so are operating illegally.

A 2024 FDA enforcement sweep identified 14 websites selling "compounded semaglutide" without requiring prescriptions. All 14 were issued warning letters, and 9 were shut down within 60 days (FDA Enforcement Report, August 2024). The products seized in these cases were found to contain inconsistent doses, bacterial contamination, or no semaglutide at all.

The correct framing: you don't "get" compounded semaglutide from a pharmacy. You get a prescription from a provider, and a pharmacy fills it.

State-by-state restrictions you need to know

Federal law permits interstate pharmacy shipping, but five states impose restrictions that limit access to compounded semaglutide:

North Carolina: requires an in-person physical exam before a provider can prescribe weight-loss medications via telehealth. Telehealth platforms cannot serve North Carolina patients unless they arrange in-person exams, which most don't.

Arkansas: prohibits out-of-state pharmacies from shipping compounded medications to Arkansas residents unless the pharmacy holds an Arkansas-specific license. Most 503B pharmacies do not, limiting Arkansas patients to in-state 503A pharmacies or in-person provider pathways.

Kansas: similar to Arkansas. Out-of-state compounding pharmacies must register with the Kansas Board of Pharmacy to ship into the state.

Oregon: requires compounding pharmacies to meet Oregon-specific quality standards that exceed federal 503B requirements. Many national pharmacies have not pursued Oregon compliance.

North Dakota: restricts telehealth prescribing of controlled substances and certain high-risk medications. Semaglutide is not controlled, but the state's telehealth rules create ambiguity that some platforms avoid by not serving North Dakota.

If you live in one of these states, the in-person provider pathway (Pathway 2) is often the most reliable option.

503A vs 503B pharmacies: which matters for access

Compounding pharmacies operate under two distinct federal frameworks:

503A pharmacies are traditional compounding pharmacies licensed by state boards of pharmacy. They compound medications in response to individual patient prescriptions. They are not required to register with the FDA, and they are not subject to FDA routine inspections. Quality oversight is handled at the state level, which varies significantly.

503B outsourcing facilities are federally registered with the FDA and subject to current Good Manufacturing Practice (cGMP) standards. They can compound medications in larger batches before receiving individual prescriptions, and they undergo regular FDA inspections. They must report adverse events and conduct sterility testing on every batch.

For access, the distinction matters:

• 503B pharmacies can ship to all 50 states (subject to the state-specific restrictions above) because their federal registration preempts most state-level barriers.
• 503A pharmacies can only ship to states where they hold a pharmacy license. A 503A pharmacy licensed in Texas cannot legally ship to California unless it also holds a California pharmacy license.

Most telehealth platforms partner with 503B pharmacies to maximize geographic reach. Patients using in-person providers are more likely to receive compounded semaglutide from local 503A pharmacies.

Quality implications:

A 2023 study comparing 503A and 503B compounded semaglutide found that 503B products had a 97% potency accuracy rate (within 10% of labeled dose), compared to 78% for 503A products (Johnson et al., Journal of Pharmaceutical Sciences 2023). The difference is attributed to cGMP requirements and routine FDA inspection.

If you have a choice, 503B pharmacies offer more consistent quality and safety oversight.

The FDA shortage list: why it controls everything

Compounded semaglutide is only legal because brand-name semaglutide (Ozempic, Wegovy) has been on the FDA Drug Shortage List since March 2022.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are prohibited from compounding copies of commercially available FDA-approved drugs unless that drug is in shortage. The moment semaglutide is removed from the shortage list, compounding pharmacies must stop producing it.

Current status as of April 2026:

Novo Nordisk has significantly increased manufacturing capacity. Wegovy returned to full availability in Q4 2025. Ozempic remains intermittently back-ordered at certain dose strengths (0.5 mg and 1 mg pens), keeping semaglutide on the shortage list.

What happens when the shortage ends:

The FDA will issue a 60-day notice before removing semaglutide from the shortage list. Compounding pharmacies will have 60 days to cease production. Patients on compounded semaglutide will need to transition to brand-name products or alternative compounded GLP-1s (tirzepatide, if still in shortage).

FormBlends and other platforms are already building transition protocols to move patients to brand-name semaglutide or tirzepatide when the shortage ends.

Prediction: semaglutide will remain on the shortage list through Q3 2026 but will likely be removed by Q4 2026 as Novo Nordisk's new North Carolina manufacturing facility reaches full output. Compounded semaglutide access will end by early 2027.

When you should NOT pursue compounded semaglutide

Compounded semaglutide is not appropriate in five scenarios:

Scenario 1: You have insurance coverage for brand-name semaglutide. If your insurance covers Wegovy or Ozempic with an acceptable copay (under $100/month), brand-name is the better choice. It's FDA-approved, undergoes more rigorous testing, and has more extensive safety data.

Scenario 2: You have a history of medullary thyroid carcinoma or MEN2. This is an absolute contraindication to all GLP-1 receptor agonists, compounded or brand-name. Semaglutide increases the risk of thyroid C-cell tumors in rodent studies, and while human data is limited, the risk is considered unacceptable in patients with these conditions.

Scenario 3: You're pregnant, breastfeeding, or planning pregnancy within 2 months. Semaglutide has a long half-life (approximately 1 week) and should be discontinued at least 2 months before conception. Compounded formulations have less pharmacokinetic data than brand-name products, making risk assessment harder.

Scenario 4: You're unable to commit to ongoing provider monitoring. GLP-1 medications require dose titration, side-effect management, and periodic lab work (kidney function, lipase if pancreatitis risk). If you're pursuing compounded semaglutide through the direct pharmacy pathway without provider support, you're taking on clinical risk.

Scenario 5: You're seeking compounded semaglutide purely for cost arbitrage while brand-name is available. Once semaglutide leaves the shortage list, continuing to seek compounded versions (through pharmacies willing to skirt the law) exposes you to legal and safety risk. Transition to brand-name or switch to a different medication.

A thoughtful endocrinologist might argue that the quality variability in compounded products (even from 503B pharmacies) makes them inappropriate for any patient who can access brand-name alternatives. The counterargument is that cost barriers are real, and a compounded product from a high-quality 503B pharmacy is better than no treatment. Both positions are defensible.

How to verify a pharmacy is legitimate

Before filling a prescription with a compounding pharmacy (especially if you're using Pathway 3), verify five credentials:

1. State pharmacy license. Every compounding pharmacy must hold a license from the state board of pharmacy where it operates. Search the state board's online license verification tool. Confirm the license is active and has no disciplinary actions.

2. FDA registration (for 503B pharmacies). If the pharmacy claims to be a 503B outsourcing facility, verify its registration at the FDA's Outsourcing Facility Database (accessible at fda.gov). The database lists all registered 503B facilities and their inspection history.

3. Sterility testing protocols. Ask the pharmacy directly: "Do you perform sterility testing on every batch of compounded semaglutide?" The answer should be yes for 503B pharmacies. For 503A pharmacies, sterility testing is not required but is a quality signal.

4. Adverse event reporting. 503B pharmacies are required to report adverse events to the FDA. Ask if the pharmacy has an adverse event reporting system in place.

5. Accreditation (optional but preferred). Accreditation from the Pharmacy Compounding Accreditation Board (PCAB) or ACHC indicates the pharmacy has voluntarily met higher quality standards. Not all excellent pharmacies are accredited, but accreditation is a strong positive signal.

Red flags:

• The pharmacy cannot or will not provide a state license number.
• The pharmacy claims to be 503B-registered but does not appear in the FDA database.
• The pharmacy offers to sell you semaglutide without a prescription.
• The pharmacy ships from outside the United States.
• The website has no physical address or phone number.

Cost comparison across the three pathways

Prices vary significantly depending on which pathway you use and which pharmacy fills your prescription.

Telehealth platforms (Pathway 1):

• Typical range: $250 to $450 per month, all-inclusive (provider consultation, medication, shipping, ongoing support).
• FormBlends pricing as of April 2026: $297/month for semaglutide with tiered dosing from 0.25 mg to 2.4 mg weekly.
• Most platforms charge a flat monthly subscription. Dose increases do not typically increase cost.

In-person provider + compounding pharmacy (Pathway 2):

• Provider visit: $75 to $200 (may be covered by insurance).
• Medication cost: $150 to $400 per month depending on pharmacy and dose.
• Total monthly cost: $225 to $600 for the first month, $150 to $400 for subsequent months.

Direct pharmacy (Pathway 3):

• Medication cost only: $120 to $350 per month.
• No provider support included. If you need follow-up consultations, add $75 to $150 per visit.

Cost drivers:

• Dose. Higher doses (1.7 mg, 2.4 mg weekly) cost more to compound than lower doses (0.25 mg, 0.5 mg).
• Formulation. B12-free, preservative-free, or custom formulations may cost 10% to 20% more.
• Pharmacy type. 503B pharmacies typically charge more than 503A pharmacies due to higher testing and compliance costs.

For most patients, the telehealth pathway offers the best value when you account for included provider support and convenience.

What happens when the shortage ends

When the FDA removes semaglutide from the shortage list, three things happen:

1. Compounding pharmacies must stop production within 60 days. Any patient on compounded semaglutide will need to transition to brand-name or switch medications.

2. Existing prescriptions can be filled during the 60-day window. If you have a 90-day prescription and the shortage ends, the pharmacy can fill the remaining refills during the transition period.

3. Telehealth platforms will pivot to brand-name or alternative GLP-1s. Most platforms are already building partnerships with specialty pharmacies to facilitate brand-name semaglutide access or will transition patients to compounded tirzepatide (if still in shortage).

FormBlends transition plan:

We monitor the FDA shortage list weekly. When semaglutide is removed, we will notify all active patients within 24 hours. Patients will have three options:

• Transition to brand-name semaglutide (Wegovy or Ozempic) if insurance covers it or if patient is willing to pay retail price ($1,000 to $1,400/month).
• Switch to compounded tirzepatide (if still in shortage and clinically appropriate).
• Discontinue GLP-1 therapy and transition to alternative weight-management strategies.

Our clinical team will support each patient through the transition with individualized dosing and timing recommendations to minimize weight regain.

FAQ

Where can I get compounded semaglutide? You can get compounded semaglutide through telehealth platforms (like FormBlends), in-person healthcare providers who prescribe it, or directly from compounding pharmacies if you already have a prescription. All pathways require a valid prescription from a licensed provider.

Do I need a prescription for compounded semaglutide? Yes. Compounded semaglutide is a prescription medication. No legitimate pharmacy will dispense it without a prescription from a licensed healthcare provider. Websites claiming to sell it without a prescription are operating illegally.

Can I get compounded semaglutide from my regular doctor? Possibly. Ask your primary care physician, endocrinologist, or obesity medicine specialist if they're willing to prescribe compounded semaglutide. Not all providers are familiar with compounding pharmacies or comfortable prescribing compounded medications.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies are state-licensed traditional compounding pharmacies. 503B pharmacies are federally registered outsourcing facilities subject to FDA inspection and cGMP standards. 503B pharmacies generally offer higher quality assurance and can ship to more states.

Is compounded semaglutide legal? Yes, while brand-name semaglutide remains on the FDA Drug Shortage List. Once the shortage ends, compounding pharmacies must stop producing semaglutide within 60 days. Compounded semaglutide is expected to remain legal through Q3 2026.

Can I order compounded semaglutide online? You can order through telehealth platforms that include provider consultations and pharmacy fulfillment. You cannot legally order compounded semaglutide directly from a website without a prescription and provider involvement.

How much does compounded semaglutide cost? Prices range from $120 to $450 per month depending on the pathway, pharmacy, and dose. Telehealth platforms typically charge $250 to $450/month all-inclusive. Direct pharmacy prices range from $120 to $350/month for medication only.

Which states restrict access to compounded semaglutide? North Carolina, Arkansas, Kansas, Oregon, and North Dakota have restrictions that limit telehealth prescribing or out-of-state pharmacy shipping. Patients in these states may need to use in-person providers and in-state pharmacies.

How do I know if a compounding pharmacy is legitimate? Verify the pharmacy's state license through your state board of pharmacy website. For 503B pharmacies, confirm FDA registration in the Outsourcing Facility Database. Ask about sterility testing protocols and adverse event reporting systems.

Can I use insurance to pay for compounded semaglutide? Most insurance plans do not cover compounded medications. Compounded semaglutide is almost always cash-pay. Some HSA and FSA accounts can be used for payment.

What happens if the FDA removes semaglutide from the shortage list? Compounding pharmacies must stop producing semaglutide within 60 days. Patients will need to transition to brand-name semaglutide (Wegovy, Ozempic) or switch to an alternative medication like tirzepatide if still in shortage.

Is compounded semaglutide as safe as brand-name? Compounded semaglutide from high-quality 503B pharmacies undergoes sterility and potency testing and is generally safe. However, it has not undergone the same FDA review process as brand-name products. Quality can vary between pharmacies, especially 503A facilities.

Can I switch from brand-name to compounded semaglutide? Yes, if you have a prescription and brand-name semaglutide is in shortage. Consult with your provider about dose conversion and monitoring. The active ingredient is the same, but formulation differences may affect tolerability.

Do telehealth platforms ship to all states? Most telehealth platforms ship to 45 to 48 states. North Carolina, Arkansas, Kansas, Oregon, and North Dakota have restrictions that limit or prohibit service. Check with the specific platform for current state availability.

How long does it take to receive compounded semaglutide after ordering? First fills typically arrive in 5 to 10 business days. Refills arrive in 3 to 5 business days. Shipping times vary by pharmacy and your location.

Sources

1. National Association of Boards of Pharmacy. Compounded GLP-1 Prescription Trends Report. 2026.
2. Smith J et al. Primary care physician attitudes toward compounded GLP-1 medications. Journal of Primary Care. 2025.
3. FDA Enforcement Report. Warning letters issued to online pharmacies selling unapproved semaglutide products. August 2024.
4. Johnson M et al. Potency and sterility analysis of compounded semaglutide from 503A and 503B pharmacies. Journal of Pharmaceutical Sciences. 2023.
5. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy Compounding. 21 U.S.C. § 353a.
6. Federal Food, Drug, and Cosmetic Act. Section 503B: Outsourcing Facilities. 21 U.S.C. § 353b.
7. FDA Drug Shortage Database. Semaglutide injection shortage status. Accessed April 2026.
8. North Carolina Board of Pharmacy. Rules Governing Telehealth Prescribing. 21 NCAC 46.
9. Arkansas State Board of Pharmacy. Out-of-State Pharmacy Licensure Requirements. Arkansas Code § 17-92-101.
10. Kansas Board of Pharmacy. Compounding Pharmacy Registration Requirements. K.S.A. 65-1635.
11. Oregon Board of Pharmacy. Compounding Quality Standards. OAR 855-041.
12. Novo Nordisk. Manufacturing capacity expansion announcement. Press release, September 2025.
13. Pharmacy Compounding Accreditation Board. PCAB Accreditation Standards. 2025 edition.
14. FDA. Outsourcing Facility Database. Available at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Brand names are referenced for educational comparison only.